Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1
Rattachement africain : au, us, fr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Cutaneous neurofibromas (cNFs) are a major cause of disfigurement in patients with Neurofibromatosis Type 1 (NF1). However, clinical trials investigating cNF treatments lack standardised outcome measures to objectively evaluate changes in cNF size and appearance. 3D imaging has been proposed as an objective standardised outcome measure however various systems exist with different features that affect useability in clinical settings. The aim of this study was to compare the accuracy, precision, feasibility, reliability and accessibility of three imaging systems. MATERIALS AND METHODS: We compared the Vectra-H1, LifeViz-Micro and Cherry-Imaging systems. A total of 58 cNFs from 13 participants with NF1 were selected for imaging and analysis. The primary endpoint was accuracy as measured by comparison of measurements between imaging systems. Secondary endpoints included reliability between two operators, precision as measured with the average coefficient of variation, feasibility as determined by time to capture and analyse an image and accessibility as determined by cost. RESULTS: There was no significant difference in accuracy between the three devices for length or surface area measurements (p > 0.05), and reliability and precision were similar. Volume measurements demonstrated the most variability compared to other measurements; LifeViz-Micro demonstrated the least measurement variability for surface area and image capture and analysis were fastest with LifeViz-Micro. LifeViz-Micro was better for imaging smaller number of cNFs (1-3), Vectra-H1 better for larger areas and Cherry for uneven surfaces. CONCLUSIONS: All systems demonstrated excellent reliability but possess distinct advantages and limitations. Surface area is the most consistent and reliable parameter for measuring cNF size in clinical trials.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1
- Date Crossref
- 01/09/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Sydney pays non établi dans la noticeUniversité ou école supérieure
-
Royal North Shore Hospital Department of Dermatology pays non établi dans la noticeÉtablissement de santé
-
Johns Hopkins University pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins Medicine pays non établi dans la noticeÉtablissement de santé
-
Assistance Publique – Hôpitaux de Paris pays non établi dans la noticeÉtablissement de santé
-
Faculty of Medicine and Health pays non établi dans la noticeUniversité ou école supérieure
-
Department of Clinical Genetics pays non établi dans la noticeÉtablissement de santé
-
Department of Neurology John Hopkins University School of Medicine Baltimore Maryland USA Department of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
Henri‐Modor Hospital Assistance Publique‐Hopital Paris (AP‐HP) Paris France Department of Dermatology pays non établi dans la noticeÉtablissement de santé
-
Henri-Modor Hospital Department of Dermatology pays non établi dans la noticeÉtablissement de santé
The University of Sydney, Department of Dermatology — Royal North Shore Hospital et Johns Hopkins University, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.